|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300072750 |
|
最近更新日期: Date of Last Refreshed on: |
2023-06-25 10:20:35 |
|
注册时间: Date of Registration: |
2023-06-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
老年新冠病毒感染者小分子抗病毒药物治疗安全性和有效性的回顾性队列研究 |
|
Public title: |
Retrospective cohort study on the safety and efficacy of small molecule antiviral drugs in elderly patients with COVID-19 |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
老年新冠病毒感染者小分子抗病毒药物治疗安全性和有效性的回顾性队列研究 |
|
Scientific title: |
Retrospective cohort study on the safety and efficacy of small molecule antiviral drugs in elderly patients with COVID-19 |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵飞 |
研究负责人: |
金鹏飞 |
|
Applicant: |
Fei Zhao |
Study leader: |
Pengfei Jin |
|
申请注册联系人电话: Applicant telephone: |
+86 182 0101 4199 |
研究负责人电话: Study leader's telephone: |
+86 10 8513 3620 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhaofei21cn@126.com |
研究负责人电子邮件: Study leader's E-mail: |
j790101@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市东城区大华路1号 |
研究负责人通讯地址: |
北京市东城区大华路1号 |
|
Applicant address: |
#1, Dahua Road, Dong District, Beijing |
Study leader's address: |
#1, Dahua Road, Dong District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京医院 |
||
|
Applicant's institution: |
Beijing Hospital |
||
|
研究负责人所在单位: |
北京医院 |
||
|
Affiliation of the Leader: |
Beijing Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023BJYYEC-031-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京医院伦理委员会 |
||
|
Name of the ethic committee: |
Beijing Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-06 00:00:00 |
||
|
伦理委员会联系人: |
张弼 |
||
|
Contact Name of the ethic committee: |
Bi Zhang |
||
|
伦理委员会联系地址: |
北京市东城区大华路1号 |
||
|
Contact Address of the ethic committee: |
#1, Dahua Road, Dong District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8513 8105 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市东城区大华路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
#1, Dahua Road, Dong District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
No |
||||||||||||||||||||||
|
Target disease: |
COVID-19 |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究基于本院的真实世界数据,旨在以老年新冠感染者为研究对象,对其服用小分子抗病毒药(包括阿兹夫定片等5种药物)治疗的有效性、安全性和影响治疗失败的因素等开展回顾性研究,以期为老年新冠感染者后续治疗提供真实世界的证据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the real world data of our hospital, this study aims to conduct a retrospective study on the effectiveness, safety and factors affecting treatment failure of small molecule antiviral drugs (including Azovudine and other five drugs) taken by the elderly infected with COVID-19, so as to provide real world evidence for the follow-up treatment of elderly infected with COVID-19. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
① 实足年龄60岁及以上;② 新冠病毒核酸检测或抗原检测阳性。 |
||||||||||||||||||||||
|
Inclusion criteria |
① The actual age is 60 years and above; ② The nucleic acid test or antigen test of COVID-19 is positive. |
||||||||||||||||||||||
|
排除标准: |
① 未进行新冠病毒核酸检测和抗原检测或新冠病毒感染状态未知;②实验室检查数据缺失。 |
||||||||||||||||||||||
|
Exclusion criteria: |
① no COVID-19 nucleic acid test and antigen test or unknown COVID-19 infection status; ② Laboratory examination data is missing. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-07-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-07-01 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
请向主要研究者提出数据分享的书面请求。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data may be made available upon written request to the study leader. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
课题组设计统一的Excel数据库进行数据录入与管理。根据所需要收集的信息进行双人数据录入并进行核对。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The research group designed a unified Excel database for data entry and management. According to the information needed to be collected, enter the data by two persons separately for double-check. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |